{Reference Type}: Journal Article {Title}: Intra-amniotic digoxin for feticide between 21 and 30 weeks of gestation: a prospective study. {Author}: Sharvit M;Klein Z;Silber M;Pomeranz M;Agizim R;Schonman R;Fishman A; {Journal}: BJOG {Volume}: 126 {Issue}: 7 {Year}: Jun 2019 {Factor}: 7.331 {DOI}: 10.1111/1471-0528.15640 {Abstract}: OBJECTIVE: Intra-amniotic injection of digoxin is a well-known method for feticide before inducing a termination of pregnancy (TOP) at 17-24 weeks of gestation. Information on its effectiveness when administered after 24 weeks of gestation is limited. This study evaluated the efficacy of intra-amniotic digoxin injection for inducing fetal demise within 18-24 hours, at 21-30 weeks of gestation, and its safety.
METHODS: Prospective cohort study.
METHODS: Tertiary university medical centre.
METHODS: Women at 21-30 weeks of gestation with a singleton pregnancy, admitted for TOP.
METHODS: Intra-amniotic injection of 2 mg of digoxin was performed 1 day before medical TOP. Fetal heart activity was evaluated by ultrasound for 18-24 hours after the injection. Serum digoxin level and maternal electrocardiogram (ECG) were evaluated 6, 10, and 20 hours after injection.
METHODS: Frequency of successful fetal demise.
RESULTS: Fifty-nine women participated in the study. The mean gestational age was 24+2  weeks (range 21+0 -30+0 ), with 29 (49.2%) beyond 24+0  weeks of gestation. Fetal cardiac activity arrest was achieved in 55/59 cases (93.2%). Normal maternal ECG recordings were noted in all cases. Mean serum digoxin levels 6 and 10 hours after injection were in the therapeutic range (1.3 ± 0.7 ng/l and 1.24 ± 0.49 ng/l, respectively) and below the toxic level (2 ng/l). Extramural delivery following digoxin did not occur. There were no cases of chorioamnionitis.
CONCLUSIONS: Intra-amniotic digoxin for feticide at 21-30 weeks of gestation in a singleton pregnancy appears effective and safe before TOP at advanced gestational ages.
CONCLUSIONS: This study shows that feticide by intra-amniotic digoxin injection at 21-30 weeks of gestation appears effective and safe.